In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 141 to 150 of 349

TitleTypeExpected publication date
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]Technology appraisal guidanceTBC
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]Technology appraisal guidanceTBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]Technology appraisal guidanceTBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Technology appraisal guidanceTBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]Technology appraisal guidanceTBC
Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]Technology appraisal guidanceTBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]Technology appraisal guidance
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]Technology appraisal guidanceTBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Technology appraisal guidanceTBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All